bioAffinity Technologies, Inc. WarrantBIAFW
About: bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Employees: 57
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.23% more ownership
Funds ownership: 2.33% [Q4 2024] → 2.56% (+0.23%) [Q1 2025]
20% less funds holding
Funds holding: 5 [Q4 2024] → 4 (-1) [Q1 2025]
38% less capital invested
Capital invested by funds: $105K [Q4 2024] → $65.2K (-$40K) [Q1 2025]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for BIAFW.
Financial journalist opinion
We haven’t received any recent news articles for BIAFW.